Latest Breaking News On - Davido watson - Page 3 : comparemela.com

Apellis Pharmaceuticals, Inc (NASDAQ:APLS) General Counsel Sells $271,960 00 in Stock

Apellis Pharmaceuticals, Inc (NASDAQ:APLS) General Counsel Sells $271,960 00 in Stock
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United statesDavido watsonRobertw bairdApellis pharmaceuticalsQuarter for apellis pharmaceuticalsWells fargo companyApellis pharmaceuticals incJennison associatesApellis pharmaceuticals price performanceAmerican investors coLisanti capital growthApellis pharmaceuticals company profileNeedham companyNews ratings for apellis pharmaceuticals dailyInstitutional investors weigh in on apellis pharmaceuticalsEnvestnet asset management inc

Apellis Pharmaceuticals, Inc (NASDAQ:APLS) General Counsel David O Watson Sells 4,184 Shares

Apellis Pharmaceuticals, Inc (NASDAQ:APLS) General Counsel David O Watson Sells 4,184 Shares
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Davido watsonRobertw bairdApellis pharmaceuticals incAdvisor group holdings incNeedham companyApellis pharmaceuticalsApellis pharmaceuticals stock downNeuberger berman groupFirst horizon advisors incApellis pharmaceuticals company profileNews ratings for apellis pharmaceuticals dailyQuarter for apellis pharmaceuticalsCim investment management incGet free reportGeneral counsel davidPharmaceuticals stock down

Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap Down Following Insider Selling

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) gapped down before the market opened on Tuesday following insider selling activity. The stock had previously closed at $65.45, but opened at $63.81. Apellis Pharmaceuticals shares last traded at $63.90, with a volume of 195,943 shares changing hands. Specifically, CAO James George Chopas sold 864 […]

James george chopasRaymond jamesDavido watsonInstitutional trading of apellis pharmaceuticalsNational bankStephens consultingApellis pharmaceuticalsNews ratings for apellis pharmaceuticals dailyJpmorgan chase coApellis pharmaceuticals incCovestor ltdApellis pharmaceuticals stockFirst horizon advisors incWealth management incGet free reportGeorge chopas

Apellis Pharmaceuticals, Inc (NASDAQ:APLS) General Counsel David O Watson Sells 4,240 Shares

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) General Counsel David O. Watson sold 4,240 shares of the stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $66.81, for a total transaction of $283,274.40. Following the transaction, the general counsel now owns 109,261 shares in the company, […]

United statesDavido watsonStephens consultingApellis pharmaceuticals stock performanceApellis pharmaceuticals company profileQuarter for apellis pharmaceuticalsApellis pharmaceuticals incJpmorgan chase coHedge funds weigh in on apellis pharmaceuticalsWealth management incNews ratings for apellis pharmaceuticals dailyFirst horizon advisors incCovestor ltdNational bankGoldman sachs groupApellis pharmaceuticals

Apellis Pharmaceuticals (NASDAQ:APLS) Trading Up 3 9%

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) were up 3.9% on Monday . The stock traded as high as $46.37 and last traded at $46.18. Approximately 1,177,061 shares were traded during mid-day trading, a decline of 57% from the average daily volume of 2,755,496 shares. The stock had previously closed at $44.44. […]

Raymond jamesAlec machielsDavido watsonPricet rowe associates incInstitutional investors weigh in on apellis pharmaceuticalsApellis pharmaceuticals incNews ratings for apellis pharmaceuticals dailyApellis pharmaceuticalsNeedham companyWells fargo companyInsider activity at apellis pharmaceuticalsJpmorgan chase coNorges bankApellis pharmaceuticals stock performanceVanguard group incGet free report